<DOC>
	<DOCNO>NCT00119496</DOCNO>
	<brief_summary>Asthmatic smoker display blunt response inhaled oral corticosteroid treatment increase risk exacerbation near fatal asthma . The prevalence smoking asthmatic run 20-30 % . Therefore , new , efficacious treatment require . Recent work demonstrate mechanism may explain steroid resistance . A commonly use drug call theophylline reverse steroid resistance laboratory study . Another commonly use drug , rosiglitazone reverse smoking induce lung inflammation laboratory study . The investigator aim study effect drug smoke asthmatic ' lung function parameter include quality life asthma control .</brief_summary>
	<brief_title>Rosiglitazone Versus Theophylline Asthmatic Smokers</brief_title>
	<detailed_description>Smoking asthmatic chronic pulmonary inflammation relatively steroid resistant . PPAR agonist ( rosiglitazone one example ) show reduce several marker inflammation human smoke animal model . This clinical study use smoke asthmatic human model smoke-induced steroid-insensitive airway inflammation evaluate efficacy rosiglitazone anti-inflammatory drug well effect low dos theophylline response low-dose inhaled corticosteroid ( LD ICS ) . Mild moderate ( per GINA guideline ) persistent-asthmatic smoker randomise study 4-week washout period withdrawn inhaled corticosteroid ( ICS ) . Subjects receive one four treatment 28 day : rosiglitazone , LD ICS , theophylline , LD ICS plus theophylline . The effect rosiglitazone LD ICS pulmonary function compare primary objective . In addition , effect theophylline plus LD ICS compare theophylline LD ICS separately . Both pulmonary anti-inflammatory systemic anti-inflammatory activity also investigate . Subjects baseline assessment pulmonary function , biomarkers systemic inflammation , sputum , exhale breath biomarkers , asthma control questionnaires safety parameter . Following 28 day treatment , parameter reassess subject .</detailed_description>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<criteria>Males females 18 60 year age ( inclusive ) . Clinical diagnosis mild moderate persistent asthma accordance Global Initiative Asthma ( GINA ) criterion Have history asthma minimum 6 month prior entry study Subjects must current cigarette smoker minimum fivepackyear smoke history Baseline FEV1 great 50 % predict ; reversibility 12 % screening , washout randomisation . Capable provide sign write informed consent comply specify study procedure . Asthma exacerbation respiratory tract infection within four week screen . Type 1 type 2 diabetes mellitus . Women lactate , pregnant , plan become pregnant . Clinically significant renal hepatic laboratory value ( e.g . AST/ALT/total bilirubin/AP &gt; 2.5 time normal value ) . Anaemia ( &lt; 11 g/dL male &lt; 10 g/dL female ) Contraindications treatment outline product label Prior history severe oedema serious fluid relate event ( e.g. , heart failure ) associate TZD The subject history significant hypersensitivity study drug Presence unstable severe angina congestive heart failure ( NYHA class III/IV ) evidence history know congestive heart failure ( NYHA class IIV ) abnormal electrocardiogram ( ECG ) , determine Investigator , subject new cardiac event ( MI , new CHF , PTCA , CABG ) within 6 month screen . History suspicion current drug abuse alcohol abuse within last 6 month . History suggestive active infection nonasthma lung pathology Clinically significant renal disease , metabolic syndrome , cirrhosis ( ChildPugh Class B/C ) , hypertension clinically significant cardiovascular , neurological , endocrine , haematological abnormality uncontrolled permitted therapy . Risk factor human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C infection Screening ( Visit 1 ) Subjects morbidly obese , define body mass index ( BMI ) &gt; 40 kg/m2 Unable perform spirometry Subjects require treatment follow asthma medication Screening ( Visit 1 ) study completion : Inhaled cromolyn sodium nedocromil ; Ipratropium bromide ; Xanthines ( theophylline preparation ) ; Leukotriene modifier ; Longacting inhale beta2agonists ( salmeterol , formoterol ) ; Oral beta2agonists . Treatment oral , intravenous intraarticular corticosteroid within 6 week Screening thereafter . Subjects take excess 1000 Î¼g daily beclomethasone ( equivalent ) within 6 week Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Corticosteroid</keyword>
	<keyword>Rosiglitazone</keyword>
	<keyword>Theophylline</keyword>
	<keyword>Beclomethasone</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Asthma</keyword>
	<keyword>Smoking</keyword>
	<keyword>Pulmonary</keyword>
</DOC>